WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 407218
Description: LY2409881 is a potent and selective IKK2 inhibitor. LY2409881 potently synergizes with histone deacetylase inhibitors in preclinical models of lymphoma through the downregulation of NF-κB. LY2409881 inhibited constitutively activated NF-κB, and caused concentration- and time-dependent growth inhibition and apoptosis in lymphoma cells. LY2409881 suppressed the activity of the NF-κB subunit p65 in lymphoma cells treated by the HDAC inhibitor romidepsin, underlying a potential mechanism of the marked synergy observed of these two drugs.
MedKoo Cat#: 407218
Chemical Formula: C24H29ClN6OS
Exact Mass: 484.18121
Molecular Weight: 485.047
Elemental Analysis: C, 59.43; H, 6.03; Cl, 7.31; N, 17.33; O, 3.30; S, 6.61
LY2409881, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Synonym: LY2409881; LY-2409881; LY 2409881.
IUPAC/Chemical Name: 2-(5-chloro-2-((3-(4-methylpiperazin-1-yl)propyl)amino)pyrimidin-4-yl)-N-cyclopropylbenzo[b]thiophene-4-carboxamide
InChi Key: BNFAYJPQCPZQND-UHFFFAOYSA-N
InChi Code: InChI=1S/C24H29ClN6OS/c1-30-10-12-31(13-11-30)9-3-8-26-24-27-15-19(25)22(29-24)21-14-18-17(4-2-5-20(18)33-21)23(32)28-16-6-7-16/h2,4-5,14-16H,3,6-13H2,1H3,(H,28,32)(H,26,27,29)
SMILES Code: O=C(C1=C(C=C(C2=NC(NCCCN3CCN(CC3)C)=NC=C2Cl)S4)C4=CC=C1)NC5CC5
The following data is based on the product molecular weight 485.047 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Deng C, Lipstein M, Rodriguez R, Serrano XO, McIntosh C, Tsai WY, Wasmuth AS,
Jaken S, O'Connor OA. The novel IKK2 inhibitor LY2409881 potently synergizes with
histone deacetylase inhibitors in preclinical models of lymphoma through the
downregulation of NF-κB. Clin Cancer Res. 2015 Jan 1;21(1):134-45. doi:
10.1158/1078-0432.CCR-14-0384. Epub 2014 Oct 29. PubMed PMID: 25355930.